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Abstract
Background: In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis
identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to
validate this expression.
Methods: Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous
ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody.
Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17
ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE).
Results: Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases.
Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed
overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed
overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation
of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype.
Conclusions: hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role
in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in
ovarian cancer.
Background
Ovarian cancer is the most deadly of all gynecologic
malignancies [1]. Because ovarian cancer is diagnosed in
Stage III or IV in 80% of cases, the prognosis is poor with
only a 44% overall survival rate [1]. However, when ovar-
ian cancer is diagnosed in the earliest stage, survival
approaches 90%. Therefore we continue to search for bet-
ter methods of early detection and for new therapeutic tar-
gets. Microarray technology allows the simultaneous
comparison of two different populations to identify unique
gene expression profiles. Use of microarray technology has
been instrumental in identifying new genes possibly
involved in the pathogenesis of ovarian cancer as well as
secretory proteins that may have clinical utility as serum
markers [2-5]. An ovarian-specific complementary DNA
(cDNA) chip showed differential expression of hRad17 in
cancer cells of long term survivors compared to short
term survivors with Stage IIIC ovarian cancer [6].
hRad17 is the human homologue of a cell cycle check-
point protein that was originally identified in yeast and is
normally expressed in the human testis [7,8]. This pro-
tein is involved in DNA damage recognition and repair
and is associated with accumulation of p53 [9]. hRad17 is
a nucleolar protein that disperses after DNA damage
[10,11] and is activated by ATR-mediated phosphoryla-
tion [12-15]. This protein interacts with DNA polymerase
ε [10] and serves as the clamp loader for the hRad 9-1-1
sliding clamp polymerase [16-19]. Both mechanisms are
important for G2 checkpoint during cell replication.
Recent data also demonstrates an interaction with DNA
ligase I [20]. Loss of the function of hRad17 or aberrant
expression may lead to malfunction of DNA repair and
ultimately the development of cancer [21,22]. Alterna-
tively, elevated expression in the setting of cancer may
lead to increased resistance to DNA-damaging agents.
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Prior studies have shown that hRad17 is upregulated
in other cancers including colon, breast, and lung cancer
[7,14,24] but no studies have thus far been conducted in
ovarian cancer. The aim this study is to validate the
over-expression of hRad17 in ovarian cancer and corre-
late this data with clinical outcomes.
Methods
Cell lines and tissue samples
All patient-derived specimens were collected and
archived under protocols approved by the Brigham and
Women’s Hospital Human Subjects Committee, Brigham
and Women’s Hospital, Boston, MA, or as an approved
use of discarded human materials as previously described
[4]. All 17 ovarian cancer cell lines (CaOV3, DOV13,
M C A S ,O V C A 3 ,O V C A 4 2 0 ,O V C A 4 2 9 ,O V C A 4 3 2 ,
OVA433, OVCA633, PEO4, SKOV3, TOV21G, RMG-1,
ES2, TOV112 D, RMUG-L, RMUG-S) and 6 human
ovarian surface epithelium (HOSE) cultures (HOSE2105,
HOSE2107, HOSE 2139, HOSE 2166, HOSE 2170,
HOSE 2177) were obtained and grown in conditions as
previously described [25]. RNA was extracted from indi-
vidual or pooled cell lines by using micro RNA extraction
kit as described by the manufacturer (Qiagen, Valencia,
CA) and quantified by fluorometry (Gemini Bio-Pro-
ducts, Inc, Calabasas, VA.). Clinicopathologic informa-
tion, including diagnosis, disease stage and grade, and
months survival, was collected from the patients’ charts.
All pathologic samples were re-reviewed for confirmation
of histologic type and diagnosis.
RNA extraction and real-time quantitative polymerase
chain reaction
Quantitative RT-PCR was performed on total RNA pre-
pared from 11 serous, 3 clear cell, 1 endometrioid, and 2
mucinous ovarian cancer cell lines as well as 6 normal
ovarian epithelial cell cultures. For the quantitative RT-
PCR studies a total of 1 μL( 0 . 1μg) cDNA was used in a
25 μL PCR mix containing 1X SYBR PCR buffer, 3 mM
MgCl2, 0.8 mM dNTP, and 0.025 U/μLA m p l i T a qG o l d
(PE Applied Biosystems, Foster City, CA). Amplification
was then performed in duplicate using primer sets pur-
chased from Sigma GenoSys (The Woodlands, TX)
(forward primer: 5’-TCCCTCTGAAGCGACACTTT-3’,
reverse primer: 5’-AGTGGCTTGAGTGGGTTCAC-3’)
and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) for normalization of input RNA in an ABI
PRISM 5700 Sequence Detector (PE Applied Biosystems).
RT-PCR was run with denaturation for 10 minutes at
95°C then 40 PCR cycles of denaturation at 95°C for
15 seconds and finally annealing or extension at 60°C for
1 minute. The relative level of hRad17 for each sample
was calculated as described [4]. In brief, the relative
amount of PCR products generated from each primer set
was determined on the basis of the Ct value. GAPDH was
used to normalize the quantity of RNA used. Its Ct value
was then subtracted from that of each target gene to
obtain the ΔCt value. The difference between the ΔCt
v a l u ea n dt h ec a l i b r a t o r( ΔCt of sample HOSE 21) was
determined as the ΔΔCt. The representative quantitative
value was expressed as 2
-ΔΔCt. The Mann Whitney U test
for nonparametric data was used to compare the distri-
butions of all cancer cell lines to normal HOSE as well as
the serous cancer cell lines to normal HOSE using SAS
software version 9.1.3 (SAS Institute Inc, Cary, NC)
Western blot analysis
Western blot analyses were performed using ovarian
tumor cell lysates from 4 ovarian cancer cell lines (ES2,
PEO4, DOV13, and OVCA 429) and 2 normal ovarian
epithelial cell cultures (HOSE 667 and HOSE 21) using
the mouse monoclonal anti-hRad17 antibody (provided
by Dr. Lan Bo Chen’s laboratory at Dana Farber Cancer
Institute, Boston, MA) previously described in immuno-
histochemistry on breast and colon tissues [7,24], and a
rabbit monoclonal antibody against phosphorylated or
activated hRad17 (Santa Cruz Biotechnology, Inc, Santa
C r u z ,C A ) .I nb r i e f ,at o t a lo f2 5μg protein for each
sample were electrophoresed on a 10% SDS-PAGE gel.
They were then transferred to a PVDF membrane for
1 hour. Membrane was blocked overnight in 5% milk in
washing buffer (TBST, created from 10 mL 1 M Tris,
20 mL of 5 M NaCl, and 1 mL Tween 20 to volume of
1 L) at 4°C and incubated manually with an anti-hRad17
or an anti-phosphorylated hRad17 using 1:1000 dilution
or 5 μL in 5 mL 5% milk in washing buffer for 1 hour
at room temperature followed by a wash in TBST for
45 min. The membrane was then incubated with sec-
ondary antibody (either goat-anti-mouse for anti-hRad17
or goat anti-rabbit for anti-hRad17-phos) 0.5 μL/mL in
washing buffer. The membrane was then again washed
for 45 min. Immunoreactivity was detected using the
ECL Chemiluminescence System (Amersham, Piscat-
away, NJ). For normalization of protein loading, the
same membrane was incubated with an anti-b-actin
monoclonal antibody (Sigma, St. Louis, MO).
Immunohistochemistry
Immunostaining was performed using a mouse mono-
clonal anti-hRad17 antibody as described above. Tissue
sections were prepared from 72 serous, 19 endome-
trioid, 10 clear cell, and 6 mucinous ovarian cancer
cases in addition to 9 benign ovarian epithelial tumors
and 6 normal ovaries. The slides were first incubated at
60°C overnight. They were then deparaffinnized in
xylene and rehydrated in graded ethanol. The slides
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5 minutes. Blocking serum was made using 10 mL TBS
with 1% bovine serum albumin (BSA). Slides were incu-
bated with the blocking serum for 30 minutes and
washed prior to incubation with anti-HRad17 antibody
(2 μg/mL) for 1.5 hours. Slides were then washed in
TBS for 20 min. The slides were then stained using the
Universal DakoCytomation EnVision System-AP with
Fast Red Substrate-Chromogen, and EnVision Labeled
Polymer, Alkaline Phosphatase (DakoCytomation, Dako,
Denmark) as described in the product’s directions. First
the slides were incubated with alkaline phosphatase
labeled polymer for 30 minutes, washed in TBS for
20 min, and incubated with the Fast Red chromogen
solution for 15 minutes. After washing in water, each
slide was then mounted and the immunoreactivity was
quantified using a semi-quantitative scoring system
described previous [26]. A weighted score was obtained
by multiplying the score (0-3) for intensity on a scale of
0 for no staining and 3 for maximum intensity of red
staining and the score for percentage stained (0-4). For
percentage stained 0 represented no staining of the spe-
cimen, 1 equal to less than 25% stained, 2 equal to
25-50% stained, 3 equal to 50-75% of specimen stained,
and 4 equal to > 75% of specimen staining positive. A
mean score was then established at 3. Scores ≥3w e r e
considered positive for hRad17 expression and scores <3
were considered negative for expression. Scores were
compared using Kruskal-Wallis analysis for nonpara-
metric data. Representative photomicrographs were
recorded by digital camera (Optronic, Inc., Muskogee,
OK).
Correlation with Patient Survival
Clinical survival data was obtained from 72 cases of
Stage 3, Grade 3 serous ovarian cancer from 1990-2003
starting with the date of the initial operation to the
most recent visit. 66 of 72 patients were deceased at the
time that the charts were reviewed. Patients were further
divided into optimally and suboptimally debulked
patients as defined by <2 cm nodules of residual disease
at the end of surgery. Survival data was correlated with
hRad17 over-expression and results obtained were
examined by Kaplan Meier survival analysis. Statistical
significance was determined by the log rank test.
Results
Quantitative RT-PCR
Quantitative real-time PCR was performed on total
R N Ap r e p a r e df r o m1 1s e r o u s ,3c l e a rc e l l ,1e n d o m e -
trioid, and 2 mucinous ovarian cancer cell lines as well
as 6 normal ovarian epithelial cell cultures. RT-PCR
demonstrated an upregulation of hRad17 RNA by 1.5-7
fold relative to HOSE. Fourteen of seventeen ovarian
cancer cell lines showed up-regulation of hRad17 RNA
compared to one of six normal ovarian epithelial cell
cultures, p = 0.0013. In addition, PCR confirmed differ-
ential expression of hRad17 RNA by subtype with 2/2
mucinous and 3/3 clear cell cancer lines compared to
8/11 serous tumor cell lines. Mucinous and clear cell
types all have 2-4 fold over-expression (Figure 1). While
the mucinous and clear cell groups were too small for
comparison, the serous cancer cell lines were also found
to have a significantly different distribution of hRad17
compared to normal with p = 0.0091.
Western blot Analysis
Next, western blot was used to confirm over-expres-
sion of total and phosphorylated hRad17 protein in 4
ovarian cancer cell lines compared to 2 normal HOSE
cell lines. Three of four ovarian cancer cell lines were
positive for over-expression of hRad17 compared to
0/2 normal HOSE. Further, ES2 and PEO4 were
strongly positive for activated hRad17 and DOV13 and
OVCA 429 were weakly positive for hRad17 expression
compared to no expression in 2 normal HOSE cell
lines (Figure 2).
Immunohistochemistry
Immunostaining of hRad17 protein was performed using
a mouse monoclonal anti-hRad17 antibody previously
described in immunohistochemistry on breast and colon
tissues [7,24]. Tissue sections were stained from 72 ser-
ous, 19 endometrioid, 10 clear cell, and 6 mucinous ovar-
ian cancers in addition to 9 benign ovarian epithelial
tumors and 6 normal ovaries. Over-expression was
defined by a standard scoring system to judge the inten-
sity and percentage stained and each slide was given a
score of hRad17 expression by two independent
reviewers who were blinded to the histologic type prior
to review. Antibody staining confirmed upregulation of
hRad17 in 53 of 107 (49.5%) ovarian carcinomas.
Immunohistochemistry further demonstrated differen-
tial expression among different subtypes of ovarian can-
cer. While only 42% (30/72) of papillary serous and 47%
(9/19) of endometrioid subtypes showed over-expres-
sion, 80% (8/10) of clear cell and 100% (6/6) of muci-
nous tumors over-expressed hRad17 (Figure 3). hRad17
over-expression was significantly higher in mucinous
and clear cell subtypes compared to serous cancer (p =
0.002, p = 0.005 respectively).
In addition, there were noted to be clear differences in
the pattern of hRad17 expression between ovarian cancer
and benign tissue as well as among the different subtypes
of ovarian cancer (Table 1). While in benign ovarian
epithelium hRad17 staining demonstrated a nuclear loca-
tion only consistent with the positive controls, the papil-
lary serous tumors exhibited hRad17 staining in the
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Figure 2 Western blot of ovarian carcinoma cell lysates showing elevated expression of both total and activated hRad17.
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Figure 1 RT-PCR showing hRad17 over-expression by ovarian cancer cell line compared to HOSE. (TOV112 D is an endometrioid type
ovarian cancer cell line.).
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Page 4 of 7cytoplasm as well as in the nucleus. Mucinous cancers
were also strongly positive in the nucleus and the cyto-
plasm. The clear cell type showed no nuclear staining but
demonstrated an unusual deeply stained speckled pattern
in the cytoplasm (Table 1). Representative photomicro-
graphs were taken and are shown in Figure 4.
Patient Survival Analysis
Patient survival data was collected on the 72 Grade 3,
Stage IIIC serous cancers that were stained for hRad17.
Kaplain-Meier curves were generated to compare
hRad17 over-expression to patient survival (Figure 5).
There was no significant difference of hRad17 expres-
sion when comparing short-term survivors to long-term
survivors with Stage IIIC, Grade 3/3 serous ovarian can-
cer. When patients were further divided into optimally
and suboptimally debulked (as defined by <2 cm resi-
dual disease at the completion of surgery) there was still
no correlation found between hRad17 over-expression
and patient survival (data not shown).
Discussion
Bao et al. initially cloned hRad17 after discovering a
unique protein that was differentially expressed in colon
cancer over normal colonic tissue [7]. hRad17 is over-
expressed in 54.7% of all breast cancers and in 68% of
those breast cancers with lymph node metastases [24].
Similarly, comparison of non-small cell lung cancer to
normal tissue has shown overexpression of hRad17 [14]
and demonstrated a significant correlation of hRad17
expression with the presence of lymph node metastases
[27]. In contrast, hRad17 is down-regulated in head and
neck cancers compared to normal oral mucosa likely
secondary to gene deletion, possibly contributing to
increased rates of DNA mutations in head and neck
tumors [28].
Our study found that hRad17 is over-expressed in
ovarian cancer, as seen in breast, colon, and lung cancer.
Further, the pattern of expression differs among sub-
types of ovarian epithelial cancers. Unlike studies in
breast and lung cancer that found over-expression cor-
related with metastases, we did not find that hRad17
over-expression correlated with survival in a subgroup
of patients with Stage IIIC serous ovarian cancer. Given
this protein’s role as in the cell cycle checkpoint, upre-
gulation of hRad17 may increase a tumor’s resistance to
platinum agents which rely on DNA damage for cell
death. This hypothesis would need to be tested in a lar-
ger group of patients with mucinous and clear cell
tumors. Alternatively, over-expression may represent
accumulation of a nonfunctional protein. Future studies
including staining the tissue sections with Ki67 may
help to elucidate this unusual staining pattern. We
would hypothesize that Ki67 overexpression would be
0
20
40
60
80
100
Pap serous Endometrioid Clear cell Mucinous
Figure 3 Percentage overexpression hRad 17 determined by
immunohistochemistry quantitative analysis comparing
different subtypes of ovarian cancer.
Table 1 Pattern of hRad17 staining by ovarian cancer
subtype
Ovarian cancer
subtype
Number of
cases
hRad17 staining Percent
over-
expressing
hRad17
Benign 9 Nuclear 13%
Serous 72 Nuclear and
cytoplasmic
42%
Endometrioid 19 Cytoplasmic 47%
Clear cell 10 Cytoplasmic 80%
Mucinous 6 Nuclear, cytoplasmic,
and stromal
100%
A B
CD
Figure 4 Representative photomicrographs of hRad17 staining
in different histologic types. A papillary serous, B endometrioid,
C mucinous, and D clear cell. Bar = 50 μm.
Young et al. Journal of Ovarian Research 2011, 4:6
http://www.ovarianresearch.com/content/4/1/6
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staining.
Other studies have suggested that abnormal expres-
sion or distribution of hRad17 may lead to a loss of
function as a DNA damage repair protein. hRad17 has
been characterized as a nucleolar protein when func-
tional in DNA repair. We found differential expression
of this protein in both the cytoplasm and nucleus
depending on the histologic type. Dispersion of hRad17
may correlate with a loss of function as a DNA repair
protein. Functional studies are needed to characterize
the role of hRad17 in these tumors, both in the nucleus
and the cytoplasm.
This study consisted of a small sample set for compar-
ison of survival data and a larger number of cases may
show a significant difference in expression between
short-term and long-term survivors. Further, the use of
immunohistochemistry to determine expression for sur-
vival comparison may be insufficiently quantitative to
see a significant difference. Limitations in the amount of
tissue did not allow for direct RNA or protein measure-
ment in each tumor. Lastly, these data do not give any
information about the role of hRad17 in ovarian cancer.
Conclusions
hRad17 is over-expressed in a majority of epithelial
ovarian cancers. Furthermore, this over-expression var-
ies by subtype suggesting a role in the pathogenesis and
behavior of these types. Functional studies are needed to
determine the potential role of this protein in the devel-
opment of ovarian cancer.
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